In this issue:
TCR T-cell therapy for HLA-A*02+ patients with PRAME+ refractory tumors
IMpower151: No benefit to atezolizumab with bevacizumab + chemo in NSCLC
Patterns in genomic mutations among patients with early-onset CRC
Later-line atezolizumab + bevacizumab ± radiotherapy for NSCLC
Lurbinectedin has modest real-world effectiveness for ES-SCLC
FUTURE-primary: patient-led follow-up feasible after curative CRC surgery
Real-world effectiveness of the addition of SRT to immunotherapy for MBM
Neoadjuvant CRT + avelumab for locally advanced rectal cancer
Savolitinib combo for osimertinib resistant EGFR-mutated MET+ NSCLC
Cancer type impacts incidence of CINV and antiemetic efficacy
Please login below to download this issue (PDF)